Opinion: Despite the fall in XRP price, analyst Dark Defender remains optimistic about its future
According to CryptoPotato, despite the roller coaster-like fluctuations in Ripple (XRP) price since the beginning of this year, renowned analyst Dark Defender remains optimistic about XRP. He believes that the price of this major asset could still break through $1. Dark Defender's optimistic analysis is based on key technical indicators such as RSI and Elliot Waves, as well as historical data.
He further divided the price into different segments, predicting prices at $0.97 and $1.5. Another well-known analyst EGRAG CRYPTO also expressed a similar view on XRP's future, predicting that XRP may break through $0.75 or fall below $0.44 in the coming months. However, Dark Defender does not believe that the asset's price will fall below $0.50.The two important events affecting XRP's price and future are Bitcoin halving scheduled for late April and the outcome of Ripple vs SEC case which if lost could have significant implications for regulations across entire crypto industry.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Uniswap.com Domain Story Resurfaces After SBF Purchase Claim
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).